Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab
JAMA Dermatology · 2024
DOI: 10.1001/jamadermatol.2024.1075 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Simon J Gunter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Adalimumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This post hoc analysis of PIONEER I and II randomized clinical trials assesses whether receiving adalimumab is associated with decreased hematologic abnormalities and increased clinical improvement in patients with hidradenitis suppurativa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Harvard Medical School, Boston, Massachusetts.
- Section of Dermatology, Department of Medicine, Carilion Clinic, Roanoke, Virginia.
- Division of Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
- Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Gunter, S. J., Holcomb, Z. E., Lam, B. D., Porter, M. L., & Kimball, A. B. (2024). Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.1075
Vancouver
Gunter SJ, Holcomb ZE, Lam BD, Porter ML, Kimball AB. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.1075
BibTeX
@article{Gunter2024,
author = {Gunter, Simon J and Holcomb, Zachary E and Lam, Barbara D and Porter, Martina L and Kimball, Alexa B},
title = {Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab},
journal = {JAMA Dermatology},
year = {2024},
doi = {10.1001/jamadermatol.2024.1075}
}
EUVIMED